Hyaluronic Acid 0.3% | Niacinamide 3%
Hyaluronic Acid 0.3% | Niacinamide 3% is a dermatology-focused preparation for prescriber-directed skin protocols. Ingredient selection should reflect the patient's diagnosis, skin type, tolerability, pregnancy status, and treatment goal.
Hyaluronic Acid 0.3% | Niacinamide 3% is a compounded topical cream or serum combining a hydrating humectant with a multifunctional skin-barrier and brightening agent. Hyaluronic acid provides surface and deeper-layer hydration while niacinamide (vitamin B3) reduces melanin transfer, supports ceramide synthesis, reduces sebaceous activity, and provides anti-inflammatory effects. Genesis Compounding prepares this as a prescription-only, patient-specific, 503A compounded preparation not FDA-approved as a compounded product.
| Active Ingredient | Pharmacologic Role |
|---|---|
| Hyaluronic Acid 0.3% | Glycosaminoglycan humectant that binds and retains water at multiple epidermal levels via CD44/RHAMM receptor interaction and passive water-binding, improving hydration, barrier function, and skin elasticity. |
| Niacinamide 3% | Water-soluble form of vitamin B3 that inhibits melanosome transfer from melanocytes to keratinocytes, stimulates ceramide and free fatty acid synthesis to restore the skin barrier, reduces sebaceous activity, and exerts anti-inflammatory effects via NAD+ modulation. |
Route: Topical. Apply a thin, even layer to cleansed skin of the affected area (typically face or neck) once or twice daily as directed by the prescriber. This preparation may be applied to dry or slightly damp skin. Niacinamide is well-tolerated across skin types and does not significantly increase photosensitivity. Sunscreen use during daytime application is nonetheless recommended as part of a complete skin care regimen.
Dosing is prescriber-determined:
- Typically applied once or twice daily to affected areas.
- A small amount (pea-sized) is adequate for facial coverage.
- Both hyaluronic acid and niacinamide have favorable tolerability profiles, allowing twice-daily use in most patients from the outset.
- Application frequency and treatment duration are determined by the prescribing clinician.
- Niacinamide 3%: Inhibits the transfer of melanosomes from melanocytes to keratinocytes (without inhibiting tyrosinase itself), thereby reducing cutaneous pigmentation. Increases NAD+ and NADH levels in keratinocytes, supporting cellular energy metabolism and antioxidant defenses. Stimulates synthesis of ceramides, free fatty acids, and involucrin to reinforce the stratum corneum barrier and reduce TEWL. Exerts anti-inflammatory effects by suppressing cytokine-driven epidermal responses and reducing sebaceous gland activity.
- Hyaluronic Acid 0.3%: High-molecular-weight HA forms a protective film on the skin surface reducing TEWL; lower-molecular-weight fractions penetrate deeper epidermal layers, promoting collagen synthesis and tissue hydration. CD44 receptor binding on keratinocytes and fibroblasts supports tissue homeostasis and wound healing.
This combination is used prescriber-directed for management of hyperpigmentation (melasma, post-inflammatory hyperpigmentation), acne-prone or oily skin, rosacea-prone sensitive skin (niacinamide's anti-inflammatory role), and skin barrier compromise with concurrent dryness. The complementary actions of HA (hydration) and niacinamide (barrier reinforcement, pigment regulation) provide a well-tolerated foundation for multi-mechanism skin improvement.
Monitoring: Clinical assessment of pigmentation, hydration, and barrier function at follow-up. Niacinamide at 3% is generally free of significant adverse effects; a small number of patients report mild flushing (usually formula-related rather than pharmacologic).
Contraindications:
- Known hypersensitivity to niacinamide, hyaluronic acid, or any formulation component.
Warnings & Precautions:
- Both ingredients are considered among the most skin-well-tolerated topical actives; adverse effects are uncommon at these concentrations.
- Avoid contact with eyes; flush with water if contact occurs.
Drug Interactions:
- No significant topical drug interactions established for either ingredient at these concentrations.
Common Side Effects: Mild transient skin flushing (rare), mild erythema at initiation. Hyaluronic acid topical: no commonly reported adverse reactions. Overall tolerability is excellent.
Store at room temperature (15°C–25°C). Keep tightly closed and away from direct sunlight and heat. Do not freeze. Use within the beyond-use date assigned by Genesis Compounding. Niacinamide may discolor at elevated temperatures; avoid storage in warm environments.
What is this formulation used for?
This preparation is primarily used prescriber-directed for hyperpigmentation (melasma, post-inflammatory dark spots), dry or compromised skin barrier, and oily/acne-prone skin management. Hyaluronic acid hydrates and soothes while niacinamide reduces pigment transfer and reinforces the skin barrier.
Can this be used with other topical medications?
Hyaluronic acid and niacinamide are both highly compatible with most topical regimens, including retinoids, azelaic acid, and sunscreen. Your prescriber will advise on layering order and compatibility with any concurrent topical prescriptions.
How quickly does niacinamide reduce hyperpigmentation?
Visible improvements in hyperpigmentation may require 4–12 weeks of consistent twice-daily use. Niacinamide reduces melanosome transfer rather than inhibiting melanin synthesis directly, so it works gradually over the skin renewal cycle.
Is this FDA-approved?
No. This is a patient-specific, prescriber-directed 503A compounded preparation from Genesis Compounding, not FDA-approved as a compounded drug.
Is this safe for sensitive skin?
Yes, both hyaluronic acid and niacinamide at these concentrations are considered among the most well-tolerated topical actives and are often used specifically for sensitive or reactive skin types.
Clinical References
Authoritative sources reviewed in preparing this clinical summary. Provided for prescriber reference; not a substitute for the prescriber’s clinical judgment.